Literature DB >> 1622120

Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer.

S Tsujitani1, Y Kakeji, H Orita, A Watanabe, S Kohnoe, H Baba, H Anai, Y Maehara, K Sugimachi.   

Abstract

To determine the group of patients for whom a biological response modifier is useful, the efficacy of postoperative adjuvant immunotherapy was investigated with regard to infiltration of dendritic cells (DC) in patients with advanced gastric cancer who underwent absolute curative resection. The infiltration of DC was classified into marked and slight. The chemotherapy group was prescribed mitomycin C and tegafur, while for the immunochemotherapy group a biological response modifier, PSK, was also prescribed in survival between the chemotherapy and immunochemotherapy groups. In patients with slight infiltration, however, the 5 - year survival rates were 0% in the chemotherapy and 15% in the immunochemotherapy group. Patients given PSK survived longer than those given chemotherapy only (P less than 0.05). Therefore, adjuvant immunotherapy may be considered for patients with advanced gastric cancer with slight infiltration of DC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622120

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Gastric cancer and the epoch of immunotherapy approaches.

Authors:  Elena Niccolai; Antonio Taddei; Domenico Prisco; Amedeo Amedei
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

Review 2.  Immunomodulatory dietary polysaccharides: a systematic review of the literature.

Authors:  Jane E Ramberg; Erika D Nelson; Robert A Sinnott
Journal:  Nutr J       Date:  2010-11-18       Impact factor: 3.271

3.  Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.

Authors:  Katsuki Ito; Hiroaki Nakazato; Akihiko Koike; Hiroshi Takagi; Shigetoyo Saji; Shozo Baba; Masayoshi Mai; Jun-ichi Sakamoto; Yasuo Ohashi
Journal:  Int J Colorectal Dis       Date:  2003-09-12       Impact factor: 2.571

4.  Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer.

Authors:  Y Maehara; S Inutsuka; H Takeuchi; H Baba; H Kusumoto; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives.

Authors:  Yoshihiko Maehara; Shunichi Tsujitani; Hiroshi Saeki; Eiji Oki; Keiji Yoshinaga; Yasunori Emi; Masaru Morita; Shunji Kohnoe; Yoshihiro Kakeji; Tokujiro Yano; Hideo Baba
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

Review 6.  Potential of Mushroom Compounds as Immunomodulators in Cancer Immunotherapy: A Review.

Authors:  Peter Amwoga Ayeka
Journal:  Evid Based Complement Alternat Med       Date:  2018-04-22       Impact factor: 2.629

7.  Identification and Verification of Potential Biomarkers in Gastric Cancer By Integrated Bioinformatic Analysis.

Authors:  Chenyu Sun; Yue Chen; Na Hyun Kim; Scott Lowe; Shaodi Ma; Zhen Zhou; Rachel Bentley; Yi-Sheng Chen; Margarita Whitaker Tuason; Wenchao Gu; Chandur Bhan; John Pocholo Whitaker Tuason; Pratikshya Thapa; Ce Cheng; Qin Zhou; Yanzhe Zhu
Journal:  Front Genet       Date:  2022-07-15       Impact factor: 4.772

Review 8.  Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.

Authors:  Daniela Cornelia Lazăr; Mihaela Flavia Avram; Ioan Romoșan; Mărioara Cornianu; Sorina Tăban; Adrian Goldiș
Journal:  World J Gastroenterol       Date:  2018-08-28       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.